Adrian Adams is Director at AMYLIN PHARMACEUTICALS INC (AMLN). They have made 7 open-market trades across 7 companies since 2008, most recently 2026-06-22.
CIK 0001248144
6 open-market purchases totalling $10.3M since 2008, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AKBA | 236,200 | $158K |
| ARLZ | 3,787,610 | $131K |
| TLPH | 22,709 | $25K |
| ACRX | 11,168 | $10K |
| IMPL | 20,000 | $5K |
| ISPH | 446,875 | — |
| AUXL | 120,134 | — |
| POZN | 2,496,359 | — |
| SEPR | 241,667 | — |
| AMLN | 10,200 | — |
| KOSP | 33,145 | — |
| Total | $328K |
Shares reported on the most recent Form 4, priced at the 2026-06-24 close. 6 holdings could not be priced and are excluded from the total.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| IMPL | BUY | 2021-08-18 | 2021-08-19 | $13.91 | $517K | +32.8% | -10.8% | -21.0% |
| ACRX | BUY | 2020-06-15 | 2020-06-15 | $1.29 | $129K | -8.3% | -25.5% | -13.1% |
| AKBA | BUY | 2019-11-20 | 2019-11-21 | $3.41 | $171K | +69.5% | +86.7% | +173.7% |
| ARLZ | BUY | 2017-03-15 | 2017-03-17 | $2.46 | $1.2M | -11.8% | -36.5% | -54.9% |
| POZN | BUY | 2015-11-11 | 2015-11-12 | $6.55 | $6.6M | N/A | N/A | N/A |
| AUXL | SELL | 2014-12-05 | 2014-12-08 | $33.97 | $1.4M | N/A | N/A | N/A |
| ACRX | BUY | 2013-05-24 | 2013-05-29 | $8.19 | $614K | -21.8% | -0.4% | -0.4% |
| SEPR | BUY | 2008-05-27 | 2008-05-27 | $20.96 | $1.0M | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.